<DOC>
	<DOCNO>NCT02316353</DOCNO>
	<brief_summary>The aim study ass long-term safety C1-esterase inhibitor ( C1-INH ) prevent hereditary angioedema ( HAE ) attack administer skin subject HAE . The safety participate subject assess 54 week . The long-term efficacy C1-INH also assess . Each eligible subject enter treatment phase , wherein subject randomize treatment either low- medium-volume C1-INH . Subjects insufficient treatment response study give opportunity undergo dose increase . The study aim enroll eligible subject complete study CSL830_3001 ( NCT01912456 ) . Subjects participate study CSL830_3001 may also participate , eligible space permit . Subjects United States ( US ) complete Treatment Period 2 allow participate Extension Period . During Extension Period participate US subject continue receive treatment open-label CSL830 additional 88 week .</brief_summary>
	<brief_title>A Study Evaluate Long-term Clinical Safety Efficacy Subcutaneously Administered C1-esterase Inhibitor Prevention Hereditary Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Hereditary Angioedema Types I II</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Males female age 6 year old . A confirmed diagnosis HAE type I II . HAE attack consecutive 2month period require acute treatment , medical attention , cause significant functional impairment . For subject use oral therapy prophylaxis HAE attack within 3 month first study visit : use stable regimen within 3 month first study visit . Incurable malignancy . Any clinical condition interfere evaluation C1INH therapy . Clinically significant history poor response C1esterase therapy management HAE . Suspected confirm diagnosis acquire HAE HAE normal C1INH . Inability HAE manage pharmacologically ondemand treatment .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>